Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

14-3-3 zeta as novel molecular target for cancer therapy.

Matta A, Siu KW, Ralhan R.

Expert Opin Ther Targets. 2012 May;16(5):515-23. doi: 10.1517/14728222.2012.668185. Epub 2012 Apr 18. Review.

PMID:
22512284
2.

14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Neal CL, Yu D.

Expert Opin Ther Targets. 2010 Dec;14(12):1343-54. doi: 10.1517/14728222.2010.531011. Review.

3.

Targeting 14-3-3zeta in cancer therapy.

Yang X, Cao W, Zhang L, Zhang W, Zhang X, Lin H.

Cancer Gene Ther. 2012 Mar;19(3):153-9. doi: 10.1038/cgt.2011.85. Epub 2011 Dec 23. Review.

PMID:
22193627
4.

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.

Cancer Sci. 2003 Jan;94(1):15-21. Review.

5.

Rac1 activation driven by 14-3-3ζ dimerization promotes prostate cancer cell-matrix interactions, motility and transendothelial migration.

Goc A, Abdalla M, Al-Azayzih A, Somanath PR.

PLoS One. 2012;7(7):e40594. doi: 10.1371/journal.pone.0040594. Epub 2012 Jul 13.

6.

14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.

Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouchi Y, Homma Y, Inoue S.

Clin Cancer Res. 2012 Oct 15;18(20):5617-27. doi: 10.1158/1078-0432.CCR-12-0281. Epub 2012 Aug 17.

7.

Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.

Arunesh GM, Shanthi E, Krishna MH, Sooriya Kumar J, Viswanadhan VN.

Expert Opin Ther Pat. 2014 Jan;24(1):5-17. doi: 10.1517/13543776.2014.848196. Epub 2013 Oct 17. Review.

PMID:
24131033
8.

The overexpression of 14-3-3ζ and Hsp27 promotes non–small cell lung cancer progression.

Zhao GY, Ding JY, Lu CL, Lin ZW, Guo J.

Cancer. 2014 Mar 1;120(5):652-63. Epub 2013 Nov 5.

PMID:
24804299
9.

Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).

Sacco E, Spinelli M, Vanoni M.

Expert Opin Ther Pat. 2012 Nov;22(11):1263-87. doi: 10.1517/13543776.2012.728586. Epub 2012 Sep 26. Review.

PMID:
23009088
10.

Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.

Das U, Kumar S, Dimmock JR, Sharma RK.

Curr Cancer Drug Targets. 2012 Jul;12(6):667-92. Review.

PMID:
22463587
11.

Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta.

Chatterjee D, Goldman M, Braastad CD, Darnowski J, Wyche JH, Pantazis P, Goodglick L.

Int J Oncol. 2004 Aug;25(2):503-9.

PMID:
15254750
12.

Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

Kabore AF, Johnston JB, Gibson SB.

Curr Cancer Drug Targets. 2004 Mar;4(2):147-63. Review.

PMID:
15032666
13.

14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells.

Macha MA, Matta A, Chauhan S, Siu KM, Ralhan R.

BMC Cancer. 2010 Nov 30;10:655. doi: 10.1186/1471-2407-10-655.

14.

Novel anticancer agents in clinical development.

Adjei AA, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S5-15. Review.

PMID:
14508076
15.

Protein kinase inhibitors against malignant lymphoma.

D'Cruz OJ, Uckun FM.

Expert Opin Pharmacother. 2013 Apr;14(6):707-21. doi: 10.1517/14656566.2013.780031. Review.

16.

An overview of the mTOR pathway as a target in cancer therapy.

Gentzler RD, Altman JK, Platanias LC.

Expert Opin Ther Targets. 2012 May;16(5):481-9. doi: 10.1517/14728222.2012.677439. Epub 2012 Apr 12. Review.

PMID:
22494490
17.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
18.

Identification of 14-3-3zeta associated protein networks in oral cancer.

Matta A, Masui O, Siu KW, Ralhan R.

Proteomics. 2016 Apr;16(7):1079-89. doi: 10.1002/pmic.201500489. Epub 2016 Mar 17.

PMID:
26857332
19.

Targeting syndecans: a promising strategy for the treatment of cancer.

Choi S, Kang DH, Oh ES.

Expert Opin Ther Targets. 2013 Jun;17(6):695-705. doi: 10.1517/14728222.2013.773313. Epub 2013 Feb 19. Review.

PMID:
23421390
20.

Modulation of cell sensitivity to antitumor agents by targeting survival pathways.

Perego P, Cossa G, Zuco V, Zunino F.

Biochem Pharmacol. 2010 Nov 15;80(10):1459-65. doi: 10.1016/j.bcp.2010.07.030. Epub 2010 Aug 3.

PMID:
20688050
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk